Trial · NCT00006011
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00006011, Phase 3, Completed, Gynecologic Oncology Group; results first posted 2014-06-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer. Trials, record NCT00006011. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00006011
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
- NCT number
- NCT00006011
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 659 participants, actual
- Lead sponsor
- Gynecologic Oncology Group
- Conditions
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer
- Interventions
- Doxorubicin Hydrochloride, Cisplatin, Filgrastim, Pegfilgrastim, Paclitaxel
- First posted
- 2003-01-27
- Last updated
- 2015-05-19
- Results first posted
- 2014-06-26
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation. | study entry up to 5 years post treatment | Recurrence is defined as discovery of disease not previously present by clinical, radiographic, and/or laboratory means or as a 50% or greater increase in the product of two perpendicular diameters from any documented lesion. Recurrence-free survival is defined as time in months the patient is alive, recurrence-free starting from the date of randomization. Intention to treat among eligible participants who receive random treatment allocation. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation. | study entry up to 5 years post treatment | participants | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation. | Arm 1 | Alive, Recurrence-Free | 159 | participants | |
| Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation. | Arm 2 | Alive, Recurrence-Free | 175 | participants | |
| Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation. | Arm 1 | Recurrence or Death | 111 | participants | |
| Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation. | Arm 2 | Recurrence or Death | 107 | participants |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Arm 1 | 288 | |
| Overall Study | STARTED | Arm 2 | 298 | |
| Overall Study | STARTED | Radiation (RT) Only | 73 | |
| Overall Study | COMPLETED | Arm 1 | 223 | |
| Overall Study | COMPLETED | Arm 2 | 221 | |
| Overall Study | COMPLETED | Radiation (RT) Only | 0 | |
| Overall Study | NOT COMPLETED | Arm 1 | 65 | |
| Overall Study | NOT COMPLETED | Arm 2 | 77 | |
| Overall Study | NOT COMPLETED | Radiation (RT) Only | 73 |
Source ClinicalTrials.gov
Adverse events120
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leukopenia | Blood and lymphatic system disorders | Arm 1 | 190 | 261 | |
| other | Leukopenia | Blood and lymphatic system disorders | Arm 2 | 250 | 278 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm 1 | 158 | 261 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm 2 | 236 | 278 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm 1 | 55 | 261 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm 2 | 116 | 278 | |
| other | Anemia | Blood and lymphatic system disorders | Arm 1 | 137 | 261 | |
| other | Anemia | Blood and lymphatic system disorders | Arm 2 | 205 | 278 | |
| other | Other Hematologic | Blood and lymphatic system disorders | Arm 1 | 44 | 261 | |
| other | Other Hematologic | Blood and lymphatic system disorders | Arm 2 | 71 | 278 |
1 to 10 of 120Source ClinicalTrials.gov
See all 120 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Arm 1 | ||
| Total, all-cause mortality | Arm 2 | ||
| Total, other adverse events | Arm 1 | 259 | 261 |
| Total, other adverse events | Arm 2 | 278 | 278 |
| Total, serious adverse events | Arm 1 | 10 | 261 |
| Total, serious adverse events | Arm 2 | 21 | 278 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U10CA027469 | Gynecologic Oncology Group | DISAIA, PHILIP J. | GYNECOLOGIC ONCOLOGY GROUP | NATIONAL CANCER INSTITUTE | 1985 to 2013 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Arm 1 vs Arm 2: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00006011
GET https://conductscience.org/api/trials/v1/NCT00006011/events?page=2